EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Entamoeba histolytica “mutator” strain with a high rate of genetic mutations assists the elucidation of drug resistance mechanisms

Yumiko Saito-Nakano iD, Shinji Izumiyama, Makoto Hirai iD, Tetsuro Kawano-Sugaya, Ghulam Jeelani, Sanjib K Sardar, Sandipan Ganguly, Tomoyoshi Nozaki iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.01210-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Yumiko Saito-Nakano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Parasitology, National Institute of Infectious Diseases, Japan Institute for Health Security, Shinjuku, Tokyo, Japan. Hauptthemen laut MEDLINE: Entamoeba histolytica, Drug Resistance, Antiprotozoal Agents, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In drug discovery, target identification and elucidation of resistance mechanisms are essential. The pathogen strains resistant to a compound of interest are useful for these purposes. As the generation of drug-resistant strains is time-consuming and often burdensome, we generated the Entamoeba histolytica strain with a high accumulation rate of genetic mutations by introducing proofreading-deficient, error-prone DNA polymerase δ mutant gene under the regulation of a tetracycline-regulatable promoter. We validated this “mutator” strain by showing higher genetic mutations accumulated during in vitro passage and, as a proof of concept, by identifying genes and their mutations responsible for resistance against miltefosine. Whole-genome analyses of the mutator strain after 12, 33, and 66 weeks of cultivation in the presence of tetracycline revealed that mutations accumulated in a time-dependent fashion, and the mutation rate of the mutator strain was approximately 60-fold higher than the mock control strain. The highly miltefosine-resistant irreversible clones were isolated from mutator-66 weeks but not from mutator-12 weeks. Whole-genome sequencing analysis of the three miltefosine highly-resistant clones identified shared mutations in three candidate genes potentially responsible for miltefosine resistance. Among them, a mutation in P4-ATPase (EHI_096620 N417K ) was worth noting, as mutations in this gene have previously been implicated in miltefosine resistance in Leishmania and Saccharomyces . We further demonstrated that exogenous expression of EHI_096620 N417K (P4-ATPase) and EHI_035500 N182I (kinase) confers miltefosine resistance. The E. histolytica mutator is a powerful tool for elucidating resistance mechanisms and potentially the modes of action of existing and future drugs against amebiasis. IMPORTANCE The protozoan parasite E. histolytica causes invasive amebiasis that is endemic in developing countries and is characterized by dysentery and liver abscesses. Metronidazole is the first-line therapeutic drug that has been used for a decade, although several adverse effects were well-documented and the risk of resistance was experimentally demonstrated. The development of alternative drugs with different modes of action is a prerequisite for future amebiasis control. To this end, elucidation of the mechanism of action and resistance of potential new antiamebic compounds is important but often challenging. To assist the process, we developed “mutator” with a high genetic mutation rate by exploitation of low-fidelity error-prone DNA polymerase δ. This genome-wide random mutagenesis system demonstrated in this study has many potentials, including rapid identification of mutations associated with resistance against new therapeutic candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Entamoeba histolyticaDrug ResistanceAntiprotozoal AgentsMutationPhosphorylcholineDNA Polymerase IIITetracyclineWhole Genome SequencingHumansProtozoan ProteinsGenome, ProtozoanMutation Rate

Stichwörter der Autor:innen

Entamoeba histolyticadrug resistanceerror-prone DNA polymerasemiltefosinemutator

Substanzen

miltefosineAntiprotozoal AgentsPhosphorylcholineDNA Polymerase IIITetracyclineProtozoan Proteins

Autor:innen und Institutionen

  • Department of Parasitology, National Institute of Infectious Diseases, Japan Institute for Health Security, Shinjuku, Tokyo, Japan.
  • Department of Tropical Medicine and Parasitology, Faculty of Medicine, Juntendo University, Bunkyo, Tokyo, Japan.
  • Department of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan.
  • Division of Parasitology, ICMR-National Institute for Research in Bacterial Infections, Kolkata, West Bengal, India.
  • Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.

ORCID-Profile: Yumiko Saito-Nakano, Makoto Hirai, Tomoyoshi Nozaki

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Saito-Nakano, Y., Izumiyama, S., Hirai, M., Kawano-Sugaya, T., Jeelani, G., Sardar, S. K., Ganguly, S., & Nozaki, T. (2025). Entamoeba histolytica “mutator” strain with a high rate of genetic mutations assists the elucidation of drug resistance mechanisms. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01210-25

Vancouver

Saito-Nakano Y, Izumiyama S, Hirai M, Kawano-Sugaya T, Jeelani G, Sardar SK, et al. Entamoeba histolytica “mutator” strain with a high rate of genetic mutations assists the elucidation of drug resistance mechanisms. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01210-25

BibTeX
@article{SaitoNakano2025,
  author = {Saito-Nakano, Yumiko and Izumiyama, Shinji and Hirai, Makoto and Kawano-Sugaya, Tetsuro and Jeelani, Ghulam and Sardar, Sanjib K and Ganguly, Sandipan and Nozaki, Tomoyoshi},
  title = {Entamoeba histolytica “mutator” strain with a high rate of genetic mutations assists the elucidation of drug resistance mechanisms},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.01210-25}
}
Kostenlos starten →